TY - JOUR
T1 - Biodistribution and tumor uptake of 67 Ga-nimotuzumab in a malignant pleural mesothelioma xenograft
AU - Izquierdo-Sánchez, Vanessa
AU - Muñiz-Hernández, Saé
AU - Vázquez-Becerra, Héctor
AU - Pacheco-Yepez, Judith
AU - Romero-Piña, Mario E.
AU - Arrieta, Oscar
AU - Medina, Luis Alberto
N1 - Publisher Copyright:
© 2018 by the authors.
PY - 2018/11/29
Y1 - 2018/11/29
N2 - Malignant pleural mesothelioma (MPM) is the most common tumor of the pulmonary pleura. It is a rare and aggressive malignancy, generally associated with continuous occupational exposure to asbestos. Only a multimodal-approach to treatment, based on surgical resection, chemotherapy and/or radiation, has shown some benefits. However, the survival rate remains low. Nimotuzumab (h-R3), an anti-EGFR (epidermal growth factor receptor) humanized antibody, is proposed as a promising agent for the treatment of MPM. The aim of this research was to implement a procedure for nimotuzumab radiolabeling to evaluate its biodistribution and affinity for EGF (epidermal growth factor) receptors present in a mesothelioma xenograft. Nimotuzumab was radiolabeled with 67 Ga; radiolabel efficiency, radiochemical purity, serum stability, and biodistribution were evaluated. Biodistribution and tumor uptake imaging studies by microSPECT/CT in mesothelioma xenografts revealed constant nimotuzumab uptake at the tumor site during the first 48 h after drug administration. In vivo studies using MPM xenografts showed a significant uptake of this radioimmunoconjugate, which illustrates its potential as a biomarker that could promote its theranostic use in patients with MPM.
AB - Malignant pleural mesothelioma (MPM) is the most common tumor of the pulmonary pleura. It is a rare and aggressive malignancy, generally associated with continuous occupational exposure to asbestos. Only a multimodal-approach to treatment, based on surgical resection, chemotherapy and/or radiation, has shown some benefits. However, the survival rate remains low. Nimotuzumab (h-R3), an anti-EGFR (epidermal growth factor receptor) humanized antibody, is proposed as a promising agent for the treatment of MPM. The aim of this research was to implement a procedure for nimotuzumab radiolabeling to evaluate its biodistribution and affinity for EGF (epidermal growth factor) receptors present in a mesothelioma xenograft. Nimotuzumab was radiolabeled with 67 Ga; radiolabel efficiency, radiochemical purity, serum stability, and biodistribution were evaluated. Biodistribution and tumor uptake imaging studies by microSPECT/CT in mesothelioma xenografts revealed constant nimotuzumab uptake at the tumor site during the first 48 h after drug administration. In vivo studies using MPM xenografts showed a significant uptake of this radioimmunoconjugate, which illustrates its potential as a biomarker that could promote its theranostic use in patients with MPM.
KW - Biomarkers
KW - Malignant pleural mesothelioma
KW - Molecular imaging
KW - Nimotuzumab
KW - Radioimmunoconjugates
UR - http://www.scopus.com/inward/record.url?scp=85057875142&partnerID=8YFLogxK
U2 - 10.3390/molecules23123138
DO - 10.3390/molecules23123138
M3 - Artículo
C2 - 30501113
AN - SCOPUS:85057875142
SN - 1420-3049
VL - 23
JO - Molecules
JF - Molecules
IS - 12
M1 - 3138
ER -